BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1733. [PMID: 12049861 DOI: 10.1016/s0140-6736(02)08651-8] [Cited by in Crossref: 1027] [Cited by in F6Publishing: 301] [Article Influence: 51.4] [Reference Citation Analysis]
Number Citing Articles
1 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
2 Asada Y, Chinen K, Yamataka K, Tokuyama J, Kurihara N, Iida S. Pathological complete response after neoadjuvant chemotherapy with FOLFOX for locally advanced sigmoid colon cancer with diverticulitis: A case report. International Journal of Surgery Case Reports 2022;90:106685. [DOI: 10.1016/j.ijscr.2021.106685] [Reference Citation Analysis]
3 Michalarea V, Smyth EC. Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma. J Thorac Dis 2017;9:2868-70. [PMID: 29221258 DOI: 10.21037/jtd.2017.08.148] [Reference Citation Analysis]
4 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fulton BA, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A, Grose D. Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. J Gastrointest Oncol 2016;7:166-72. [PMID: 27034782 DOI: 10.3978/j.issn.2078-6891.2015.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116-2121. [PMID: 14647147 DOI: 10.1038/sj.bjc.6601372] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
7 Woolston CM, Madhusudan S, Soomro IN, Lobo DN, Reece-Smith AM, Parsons SL, Martin SG. Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma. Redox Biol 2013;1:285-91. [PMID: 24024162 DOI: 10.1016/j.redox.2013.04.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
8 Ellis R, Cole AJ, O'Hare J, Whitten G, Crowther K, Harrison C. Coincidental splenic irradiation and risk of functional hyposplenism in oesophageal cancer treatment. J Med Imaging Radiat Oncol 2021. [PMID: 34405578 DOI: 10.1111/1754-9485.13310] [Reference Citation Analysis]
9 Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC: Treatment for Barrett’s oesophagus Cochrane Database Syst Rev. 2010;CD004060. [PMID: 20091557 DOI: 10.1002/14651858.cd004060.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Patel N, Foley KG, Powell AG, Wheat JR, Chan D, Fielding P, Roberts SA, Lewis WG. Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer. Eur J Nucl Med Mol Imaging 2019;46:801-9. [PMID: 30116837 DOI: 10.1007/s00259-018-4118-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:480-6. [PMID: 27637603 DOI: 10.1007/s00268-016-3649-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. [PMID: 24314264 DOI: 10.1186/1471-2288-13-152] [Cited by in Crossref: 270] [Cited by in F6Publishing: 259] [Article Influence: 30.0] [Reference Citation Analysis]
14 Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, Kondo S. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol. 2011;164:50-56. [PMID: 21352198 DOI: 10.1111/j.1365-2249.2010.04311.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
15 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wajed SA, Veeramootoo D, Shore AC. Video. Surgical optimisation of the gastric conduit for minimally invasive oesophagectomy. Surg Endosc. 2012;26:271-276. [PMID: 21858577 DOI: 10.1007/s00464-011-1855-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
17 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
18 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014; 6(10): 403-406 [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
19 Sillah K, Griffiths EA, Pritchard SA, Swindell R, West CM, Page R, Welch IM. Clinical impact of tumour involvement of the anastomotic doughnut in oesophagogastric cancer surgery. Ann R Coll Surg Engl 2009;91:195-200. [PMID: 19220937 DOI: 10.1308/003588409X359268] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
20 Park JS, Van der Wall H, Kennedy C, Falk GL. Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated? World J Gastrointest Surg 2021; 13(10): 1235-1244 [PMID: 34754391 DOI: 10.4240/wjgs.v13.i10.1235] [Reference Citation Analysis]
21 Keld RR, Ang YS. Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine? World J Gastroenterol 2011; 17(23): 2781-2790 [PMID: 21734785 DOI: 10.3748/wjg.v17.i23.2781] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Krasna MJ. Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'. Drugs Aging 2009;26:185-94. [PMID: 19358615 DOI: 10.2165/00002512-200926030-00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 19(48): 9282-9293 [PMID: 24409055 DOI: 10.3748/wjg.v19.i48.9282] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
24 Takeno A, Takiguchi S, Yamasaki M, Miyata H, Kawabata R, Nushijima Y, Makino T, Fujiwara Y, Nakajima K, Nishida T, Mori M, Doki Y. A suspected [18F]fluorodeoxyglucose positron emission tomography-negative metastatic lymph node successfully diagnosed by laparoscopic staging in esophageal cancer: report of two cases. Surg Today 2009;39:888-91. [PMID: 19784729 DOI: 10.1007/s00595-009-3952-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 van Hootegem SJM, Smithers BM, Gotley DC, Brosda S, Thomson IG, Thomas JM, Gartside M, van Lanschot JJB, Lagarde SM, Wijnhoven BPL, Barbour AP. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol 2019;26:2375-84. [PMID: 30941657 DOI: 10.1245/s10434-019-07322-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
26 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
27 Goldfarb M, Brower S, Schwaitzberg SD. Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010;24:304-334. [PMID: 19572178 DOI: 10.1007/s00464-009-0583-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
28 Suttie SA, Li AG, Quinn M, Park KG. The impact of operative approach on outcome of surgery for gastro-oesophageal tumours. World J Surg Oncol 2007;5:95. [PMID: 17708773 DOI: 10.1186/1477-7819-5-95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Shih LH, Chen SW, Li SH. Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis. Sci Rep 2018;8:15073. [PMID: 30305678 DOI: 10.1038/s41598-018-33400-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Cáncer de esófago. Medicina Clínica 2008;130:423-8. [DOI: 10.1157/13117853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Khan O, Goh S, Byrne B, Somers S, Mercer S, Toh S. Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours. World J Surg. 2011;35:2245-2251. [PMID: 21850599 DOI: 10.1007/s00268-011-1235-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
34 MacGregor TP, Carter R, Gillies RS, Findlay JM, Kartsonaki C, Castro-Giner F, Sahgal N, Wang LM, Chetty R, Maynard ND, Cazier JB, Buffa F, McHugh PJ, Tomlinson I, Middleton MR, Sharma RA. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma. Sci Rep 2018;8:7265. [PMID: 29739952 DOI: 10.1038/s41598-018-24232-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Jonsson L, Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Eberhard J, Jirström K. High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res 2014;2:11. [PMID: 24963396 DOI: 10.1186/2050-7771-2-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
36 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
37 Yamauchi T, Fujishima F, Hashimoto M, Tsunokake J, Akaishi R, Gokon Y, Ueki S, Ozawa Y, Fukutomi T, Okamoto H, Sato C, Taniyama Y, Nakamura T, Nakaya N, Kamei T, Sasano H. Necroptosis in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Its Correlation with Tumor-Infiltrating Lymphocytes. Cancers (Basel) 2021;13:4473. [PMID: 34503283 DOI: 10.3390/cancers13174473] [Reference Citation Analysis]
38 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:105. [PMID: 33836789 DOI: 10.1186/s12957-021-02208-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhao P, Yan W, Fu H, Lin Y, Chen KN. Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis. Thorac Cancer 2018;9:1048-55. [PMID: 29927075 DOI: 10.1111/1759-7714.12787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
40 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
41 Yoon HH, Lowe VJ, Cassivi SD, Romero Y. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am. 2009;38:105-120, ix. [PMID: 19327570 DOI: 10.1016/j.gtc.2009.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med 2011;2:879-85. [PMID: 22977592 DOI: 10.3892/etm.2011.308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
43 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
44 Beasley WD, Jefferies MT, Gilmour J, Manson JM. A single surgeon's series of transthoracic oesophageal resections. Ann R Coll Surg Engl 2014;96:151-6. [PMID: 24780676 DOI: 10.1308/003588414X13814021677359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 2006;94:363-71. [PMID: 16465172 DOI: 10.1038/sj.bjc.6602960] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
46 Kanemura T, Miyata H, Makino T, Tanaka K, Sugimura K, Hamada-Uematsu M, Mizote Y, Uchida H, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Immunoregulatory influence of abundant MFG-E8 expression by esophageal cancer treated with chemotherapy. Cancer Sci 2018;109:3393-402. [PMID: 30156356 DOI: 10.1111/cas.13785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
47 van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:1389-94. [PMID: 16670722 DOI: 10.1038/sj.bjc.6603134] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
48 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
49 Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res 2017;23:7543-9. [PMID: 28972045 DOI: 10.1158/1078-0432.CCR-16-3142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
50 Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol 2013;31:237-50. [PMID: 23608443 DOI: 10.1016/j.clindermatol.2012.08.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
51 Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg 2017;104:1816-28. [PMID: 28944954 DOI: 10.1002/bjs.10627] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
52 Reid TD, Chan DS, Roberts SA, Crosby TD, Williams GT, Lewis WG. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer and the predictive role of endoluminal ultrasonography. Br J Cancer 2012;107:1925-31. [PMID: 23169281 DOI: 10.1038/bjc.2012.511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
53 Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, Chen KN. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget 2016;7:4531-41. [PMID: 26673820 DOI: 10.18632/oncotarget.6554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
54 Garutti M, Buriolla S, Bertoli E, Vitale MG, Rossi E, Schinzari G, Minisini AM, Puglisi F. "To Anticipate": Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. Cancers (Basel) 2020;12:E1941. [PMID: 32708968 DOI: 10.3390/cancers12071941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
56 Anderegg MCJ, van der Sluis PC, Ruurda JP, Gisbertz SS, Hulshof MCCM, van Vulpen M, Mohammed NH, van Laarhoven HWM, Wiezer MJ, Los M, van Berge Henegouwen MI, van Hillegersberg R. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2017;24:2282-2290. [PMID: 28424936 DOI: 10.1245/s10434-017-5827-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
57 Shen LY, Fan MY, Dong B, Yan WP, Chen KN. Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma. Oncol Lett 2017;14:4835-40. [PMID: 29085488 DOI: 10.3892/ol.2017.6772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Schlick CJR, Khorfan R, Odell DD, Merkow RP, Bentrem DJ. Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors? Ann Surg Oncol 2020;27:1496-507. [PMID: 31933223 DOI: 10.1245/s10434-019-08176-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Molina JC, Al-Hinai A, Gosseling-Tardif A, Bouchard P, Spicer J, Mulder D, Mueller CL, Ferri LE. Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers-11-Year Experience at a High-Volume North American Center. J Gastrointest Surg. 2019;23:43-50. [PMID: 29663302 DOI: 10.1007/s11605-018-3746-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
60 van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005;9:54-61. [PMID: 15623445 DOI: 10.1016/j.gassur.2004.09.055] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
61 Lyratzopoulos G, Barbiere JM, Gajperia C, Rhodes M, Greenberg DC, Wright KA. Trends and variation in the management of oesophagogastric cancer patients: a population-based survey. BMC Health Serv Res 2009;9:231. [PMID: 20003488 DOI: 10.1186/1472-6963-9-231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
62 Chen YH, Li SH, Lu HI, Lo CM. Prognostic Value of SDF-1α Expression in Patients with Esophageal Squamous Cell Carcinoma Receiving Esophagectomy. Cancers (Basel) 2020;12:E1067. [PMID: 32344892 DOI: 10.3390/cancers12051067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Dixit S, Tilston M, Peter WM. Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Med Oncol. 2010;27:242-248. [PMID: 19308739 DOI: 10.1007/s12032-009-9199-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
64 Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30. [PMID: 15194636 DOI: 10.1136/gut.2003.025080] [Cited by in Crossref: 402] [Cited by in F6Publishing: 350] [Article Influence: 22.3] [Reference Citation Analysis]
65 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
66 Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. J Gastrointest Oncol 2016;7:506-14. [PMID: 27563439 DOI: 10.21037/jgo.2016.06.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
67 Song S, Chie EK, Kim HJ, Kang CH, Kim YT, Kim JH, Park CI. Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus. Cancer Res Treat 2013;45:202-9. [PMID: 24155679 DOI: 10.4143/crt.2013.45.3.202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
68 Wilke H, Stahl M. [Therapy in gastric cancer. From an oncological perspective]. Chirurg. 2009;80:1023-1027. [PMID: 19902288 DOI: 10.1007/s00104-009-1735-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
69 Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 2010;15:270-84. [PMID: 20203174 DOI: 10.1634/theoncologist.2009-0293] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
70 Malik V, Keogan M, Gilham C, Duffy G, Ravi N, Reynolds JV. FDG-PET scanning in the management of cancer of the oesophagus and oesophagogastric junction: early experience with 100 consecutive cases. Ir J Med Sci 2006;175:48-54. [PMID: 17312829 DOI: 10.1007/BF03167967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
71 Kelley ST, Coppola D, Karl RC. Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg. 2004;8:227-231; discussion 231-232. [PMID: 15019913 DOI: 10.1016/j.gassur.2003.11.024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
72 Zhang JL, Wang HY, Yang Q, Lin SY, Luo GY, Zhang R, Xu GL. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer. World J Gastroenterol 2015; 21(14): 4240-4247 [PMID: 25892874 DOI: 10.3748/wjg.v21.i14.4240] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
73 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Manzini G, Klotz U, Henne-Bruns D, Kremer M. Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials. World J Gastrointest Oncol 2020; 12(1): 113-123 [PMID: 31966919 DOI: 10.4251/wjgo.v12.i1.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Dutta S, Going JJ, Crumley AB, Mohammed Z, Orange C, Edwards J, Fullarton GM, Horgan PG, McMillan DC. The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 2012;106:702-10. [PMID: 22240784 DOI: 10.1038/bjc.2011.610] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
76 Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. Cancer Manag Res 2020;12:9539-49. [PMID: 33061640 DOI: 10.2147/CMAR.S261182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci 2010;55:3304-14. [PMID: 20300841 DOI: 10.1007/s10620-010-1187-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
78 Lund M, Alexandersson von Döbeln G, Nilsson M, Winter R, Lundell L, Tsai JA, Kalman S. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial. Radiat Oncol 2015;10:16. [PMID: 25582305 DOI: 10.1186/s13014-014-0310-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
79 Akaishi R, Fujishima F, Ishida H, Tsunokake J, Yamauchi T, Gokon Y, Ueki S, Fukutomi T, Okamoto H, Takaya K, Sato C, Taniyama Y, Nakamura T, Nakaya N, Kamei T, Sasano H. Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma. Esophagus 2022. [PMID: 34999996 DOI: 10.1007/s10388-021-00904-3] [Reference Citation Analysis]
80 Zhou Z, Nimeiri HS, Benson AB 3rd. Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med 2013;1:11. [PMID: 25332956 DOI: 10.3978/j.issn.2305-5839.2013.01.01] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
81 Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, Rahman S, Devonshire G, Lloyd MA, Walters ZS, Fitzgerald RC, Rose-Zerilli MJJ, Underwood TJ, On Behalf Of Occams. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:3394. [PMID: 34298611 DOI: 10.3390/cancers13143394] [Reference Citation Analysis]
82 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
83 Davies AR, Forshaw MJ, Khan AA, Noorani AS, Patel VM, Strauss DC, Mason RC. Transhiatal esophagectomy in a high volume institution. World J Surg Oncol 2008;6:88. [PMID: 18715498 DOI: 10.1186/1477-7819-6-88] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
84 Aprile G, Sobrero A. Highlights from the 2008 Gastrointestinal Cancers Symposium. European Journal of Cancer Care 2009;18:10-7. [DOI: 10.1111/j.1365-2354.2008.01022.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
85 Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, Siersema PD, van Dekken H, van Lanschot JJ. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch. 2005;446:497-504. [PMID: 15838647 DOI: 10.1007/s00428-005-1243-1] [Cited by in Crossref: 234] [Cited by in F6Publishing: 195] [Article Influence: 13.8] [Reference Citation Analysis]
86 Furukawa H, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. Cancer Sci 2018;109:412-21. [PMID: 29168598 DOI: 10.1111/cas.13454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
87 Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932. [PMID: 17680242 DOI: 10.1007/s00259-007-0521-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
88 Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B, Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S, Cheng C. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer 2022;10:e003497. [PMID: 35022193 DOI: 10.1136/jitc-2021-003497] [Reference Citation Analysis]
89 Yang H, Fu JH. Progress in surgery-based multimodality therapy for resectable esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3471-3475 [DOI: 10.11569/wcjd.v20.i35.3471] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
90 Chen YH, Lu HI, Wang YM, Lo CM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH. The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. Oncotarget 2017;8:96190-202. [PMID: 29221198 DOI: 10.18632/oncotarget.21878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
91 Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33:27-37. [DOI: 10.1007/s00259-006-0133-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
92 Lemini R, Díaz Vico T, Trumbull DA, Attwood K, Spaulding AC, Elli EF, Colibaseanu DT, Kukar M, Gabriel E. Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators. J Gastrointest Oncol 2021;12:1963-72. [PMID: 34790364 DOI: 10.21037/jgo-20-337] [Reference Citation Analysis]
93 Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, Yu J. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694-e701. [PMID: 22337686 DOI: 10.1259/bjr/29946900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
94 Parameswaran R, Veeramootoo D, Krishnadas R, Cooper M, Berrisford R, Wajed S. Comparative experience of open and minimally invasive esophagogastric resection. World J Surg. 2009;33:1868-1875. [PMID: 19609827 DOI: 10.1007/s00268-009-0116-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
95 Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919838963. [PMID: 31044021 DOI: 10.1177/1758835919838963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, Schoppmann SF. Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study. Eur Surg. 2018;50:249-255. [PMID: 30546384 DOI: 10.1007/s10353-018-0552-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
97 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
98 Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35. [PMID: 15447788 DOI: 10.1186/1741-7015-2-35] [Cited by in Crossref: 156] [Cited by in F6Publishing: 130] [Article Influence: 8.7] [Reference Citation Analysis]
99 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
100 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
101 Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, West NP, Wright AI, Treanor D, Hewitt LC, Allum WH, Cunningham D, Hayden JD, Grabsch HI. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget 2016;7:77565-75. [PMID: 27769054 DOI: 10.18632/oncotarget.12723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
102 Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 2011;68:863-70. [PMID: 21286719 DOI: 10.1007/s00280-011-1556-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
103 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
104 Zhang L, Li W, Lyu X, Song Y, Mao Y, Wang S, Huang J. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Chin J Cancer Res 2017;29:149-55. [PMID: 28536494 DOI: 10.21147/j.issn.1000-9604.2017.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
105 Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 2016;7:50624-34. [PMID: 27244882 DOI: 10.18632/oncotarget.9562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
106 Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer. 2014;14:490. [PMID: 25001061 DOI: 10.1186/1471-2407-14-490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
107 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
108 Kelly MD, Walsh TN. Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ J Surg 2003;73:976-8. [PMID: 14632885 DOI: 10.1046/j.1445-2197.2003.t01-20-.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Li X, Wu Z, Mei Q, Li X, Guo M, Fu X, Han W. Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Br J Cancer 2013;109:2266-78. [PMID: 24022190 DOI: 10.1038/bjc.2013.548] [Cited by in Crossref: 113] [Cited by in F6Publishing: 121] [Article Influence: 12.6] [Reference Citation Analysis]
110 Kucharczuk JC, Kaiser LR. Radical lobectomy, esophagectomy, and mediastinal dissections for intrathoracic malignancy. Surg Oncol Clin N Am 2005;14:499-509, vi. [PMID: 15978426 DOI: 10.1016/j.soc.2005.05.001] [Reference Citation Analysis]
111 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
112 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
113 Burdall OC, Boddy AP, Fullick J, Blazeby J, Krysztopik R, Streets C, Hollowood A, Barham CP, Titcomb D. A comparative study of survival after minimally invasive and open oesophagectomy. Surg Endosc. 2015;29:431-437. [PMID: 25125095 DOI: 10.1007/s00464-014-3694-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
114 Semenkovich TR, Panni RZ, Hudson JL, Thomas T, Elmore LC, Chang SH, Meyers BF, Kozower BD, Puri V. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. J Thorac Cardiovasc Surg 2018;155:2221-2230.e1. [PMID: 29428700 DOI: 10.1016/j.jtcvs.2018.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
115 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
116 Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012;31:399-408. [PMID: 22572013 DOI: 10.5732/cjc.011.10406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
117 Lordick F, Gockel I. Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innov Surg Sci 2016;1:3-11. [PMID: 31579713 DOI: 10.1515/iss-2016-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Mukherji D, Benepal T. A review of in vitro and in vivo models of oesophageal and gastric cancer. Expert Opin Drug Discov 2009;4:1267-79. [PMID: 23480466 DOI: 10.1517/17460440903410203] [Reference Citation Analysis]
120 Knauer M, Haid A, Ammann K, Lang A, Offner F, Türtscher M, Cerkl P, Wenzl E. Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. World J Surg Oncol 2007;5:114. [PMID: 17927839 DOI: 10.1186/1477-7819-5-114] [Reference Citation Analysis]
121 Han D, van Akkooi ACJ, Straker RJ 3rd, Shannon AB, Karakousis GC, Wang L, Kim KB, Reintgen D. Current management of melanoma patients with nodal metastases. Clin Exp Metastasis 2021. [PMID: 33961168 DOI: 10.1007/s10585-021-10099-7] [Reference Citation Analysis]
122 Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med 2016;14:313. [PMID: 27846884 DOI: 10.1186/s12967-016-1070-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
123 Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725-1730. [PMID: 19436301 DOI: 10.1038/sj.bjc.6605070] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
124 Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma? J Surg Oncol 2020;122:412-21. [PMID: 32462769 DOI: 10.1002/jso.25990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Chettouh H, Mowforth O, Galeano-Dalmau N, Bezawada N, Ross-Innes C, MacRae S, Debiram-Beecham I, O'Donovan M, Fitzgerald RC. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut 2018;67:1942-9. [PMID: 29084829 DOI: 10.1136/gutjnl-2017-314026] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
126 Platz TA, Nurkin SJ, Fong MK, Groman A, Flaherty L, Malhotra U, Levea CM, Yendamuri S, Warren GW, Nava HR. Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma. J Gastrointest Oncol. 2013;4:137-143. [PMID: 23730509 DOI: 10.3978/j.issn.2078-6891.2013.007] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
127 Sawada G, Niida A, Hirata H, Komatsu H, Uchi R, Shimamura T, Takahashi Y, Kurashige J, Matsumura T, Ueo H, Takano Y, Ueda M, Sakimura S, Shinden Y, Eguchi H, Sudo T, Sugimachi K, Yamasaki M, Tanaka F, Tachimori Y, Kajiyama Y, Natsugoe S, Fujita H, Tanaka Y, Calin G, Miyano S, Doki Y, Mori M, Mimori K. An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma. PLoS One 2015;10:e0139808. [PMID: 26465158 DOI: 10.1371/journal.pone.0139808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
128 Zhao Q, Chen S, Feng JF. A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio. Oncotarget 2017;8:103535-42. [PMID: 29262582 DOI: 10.18632/oncotarget.21989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
129 Qian Y, Zhang CJ, Chen ZD. Assessment of life quality of esophageal cancer patients received chemotherapy. Shijie Huaren Xiaohua Zazhi 2006; 14(18): 1819-1823 [DOI: 10.11569/wcjd.v14.i18.1819] [Reference Citation Analysis]
130 Davarzani N, Hewitt LC, Hale MD, Melotte V, Nankivell M, Hutchins GGA, Cunningham D, Allum WH, Langley RE, Jolani S, Grabsch HI. Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. Dis Esophagus 2020;33:doaa058. [PMID: 32591823 DOI: 10.1093/dote/doaa058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Gockel I, Heckhoff S, Messow CM, Kneist W, Junginger T. Transhiatal and transthoracic resection in adenocarcinoma of the esophagus: does the operative approach have an influence on the long-term prognosis. World J Surg Oncol. 2005;3:40. [PMID: 15978128 DOI: 10.1186/1477-7819-3-40] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
132 Biebl M, Andreou A, Chopra S, Denecke C, Pratschke J. Upper Gastrointestinal Surgery: Robotic Surgery versus Laparoscopic Procedures for Esophageal Malignancy. Visc Med 2018;34:10-5. [PMID: 29594164 DOI: 10.1159/000487011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
133 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A, Segelov E. The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. Cancer Manag Res 2021;13:2567-79. [PMID: 33762848 DOI: 10.2147/CMAR.S262870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
136 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Sun L, Zhang H, Wu K. Esophageal Cancer: Current Options for Therapeutic Management. Gastrointest Tumors 2014;1:105-13. [PMID: 26674591 DOI: 10.1159/000362907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
138 Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol 2018;41:254-8. [PMID: 26703814 DOI: 10.1097/COC.0000000000000258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
139 Dehal A, Graff-Baker AN, Vuong B, Fischer T, Klempner SJ, Chang SC, Grunkemeier GL, Bilchik AJ, Goldfarb M. Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. J Gastrointest Surg. 2018;22:242-249. [PMID: 28933016 DOI: 10.1007/s11605-017-3566-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
140 Reid TD, Sanyaolu LN, Chan D, Williams GT, Lewis WG. Relative prognostic value of TNM7 vs TNM6 in staging oesophageal cancer. Br J Cancer 2011;105:842-6. [PMID: 21847117 DOI: 10.1038/bjc.2011.320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
141 Fan M, Lin Y, Pan J, Yan W, Dai L, Shen L, Chen K. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis. Thorac Cancer. 2016;7:173-181. [PMID: 27042219 DOI: 10.1111/1759-7714.12299] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
142 De Silva N, Fitzgerald R. Barrett's oesophagus and oesophageal adenocarcinoma. Medicine 2015;43:202-9. [DOI: 10.1016/j.mpmed.2015.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9:e87705. [PMID: 24498358 DOI: 10.1371/journal.pone.0087705] [Cited by in Crossref: 202] [Cited by in F6Publishing: 183] [Article Influence: 25.3] [Reference Citation Analysis]
144 Wang ZQ, Chen LQ, Yuan Y, Wang WP, Niu ZX, Yang YS, Cai J. Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21(12): 3720-3730 [PMID: 25834341 DOI: 10.3748/wjg.v21.i12.3720] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
145 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Butt J, Kandel G. Barrett esophagus: when to endoscope. Clin Endosc 2014;47:40-6. [PMID: 24570882 DOI: 10.5946/ce.2014.47.1.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
147 Kötz BS, Croft S, Ferry DR. Do delays between diagnosis and surgery in resectable oesophageal cancer affect survival? A study based on West Midlands cancer registration data. Br J Cancer 2006;95:835-40. [PMID: 16969353 DOI: 10.1038/sj.bjc.6603333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
148 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
149 Tong DK, Law S. Management of oesophageal cancer. Indian J Surg 2009;71:317-25. [PMID: 23133184 DOI: 10.1007/s12262-009-0087-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
150 Nguyen TH, Tran HX, Thai TT, La DM, Tran HD, Le KT, Pham VTN, Le ANT, Nguyen BH. Feasibility and Safety of Laparoscopic Radical Colectomy for T4b Colon Cancer at a University Hospital in Vietnam. Biomed Res Int 2020;2020:1762151. [PMID: 33224972 DOI: 10.1155/2020/1762151] [Reference Citation Analysis]
151 Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 2016;34:2721-2727. [PMID: 27298411 DOI: 10.1200/jco.2015.65.7692] [Cited by in Crossref: 115] [Cited by in F6Publishing: 65] [Article Influence: 19.2] [Reference Citation Analysis]
152 Huang B, Chan EG, Pennathur A, Luketich JD, Zhang J. The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis. BMC Cancer 2021;21:1334. [PMID: 34911468 DOI: 10.1186/s12885-021-08896-0] [Reference Citation Analysis]
153 Rao S, Cunningham D. Survival from cancer of the oesophagus in England and Wales up to 2001. Br J Cancer 2008;99 Suppl 1:S14-5. [PMID: 18813245 DOI: 10.1038/sj.bjc.6604573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
154 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
155 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
156 Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res 2020;9:F1000 Faculty Rev-1189. [PMID: 33042518 DOI: 10.12688/f1000research.22926.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Boulva K, Apte S, Yu A, Tran A, Shorr R, Song X, Ong M, Nessim C. Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. Cancers (Basel) 2021;13:1905. [PMID: 33920967 DOI: 10.3390/cancers13081905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Bhudia J, Glynne-Jones R, Smith T, Hall M. Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clin Colon Rectal Surg 2020;33:287-97. [PMID: 32968364 DOI: 10.1055/s-0040-1713746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427-1433. [PMID: 26554656 DOI: 10.1038/bjc.2015.354] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
161 Zhou T, Fu H, Dong B, Dai L, Yang Y, Yan W, Shen L. HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair. Thorac Cancer 2020;11:3071-85. [PMID: 31568655 DOI: 10.1111/1759-7714.13142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
162 Shimada A, Takeuchi H, Fukuda K, Suda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. Esophagus 2018;15:209-16. [PMID: 30225740 DOI: 10.1007/s10388-018-0615-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Zheng ZY, Yang PL, Luo W, Yu SX, Xu HY, Huang Y, Li RY, Chen Y, Xu XE, Liao LD, Wang SH, Huang HC, Li EM, Xu LY. STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:901. [PMID: 33670049 DOI: 10.3390/cancers13040901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
165 Nusrath S, Thammineedi SR, Vijaya Narsimha Raju KV, Patnaik SC, Pawar S, Santa A, Rajappa SJ, Mallavarapu KM, Raju K, Murthy S. Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. Rambam Maimonides Med J 2019;10. [PMID: 29993360 DOI: 10.5041/RMMJ.10339] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Mirza A, Pritchard S, Welch I. Is surgery in the elderly for oesophageal cancer justifiable? Results from a single centre. ISRN Surg 2013;2013:609252. [PMID: 24205444 DOI: 10.1155/2013/609252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
167 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
168 Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes R, Beneck D, Paul S, Stiles BM, Zhang Y, Schrump DS. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol 2011;6:1121-7. [PMID: 21532508 DOI: 10.1097/JTO.0b013e31821529a9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
169 Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372. [PMID: 20833740 DOI: 10.1136/bmj.c4372] [Cited by in Crossref: 201] [Cited by in F6Publishing: 188] [Article Influence: 16.8] [Reference Citation Analysis]
170 Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med 2017;15:39. [PMID: 28222797 DOI: 10.1186/s12967-017-1140-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
171 Lao-Sirieix P, Fitzgerald RC. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012;9:278-287. [PMID: 22430857 DOI: 10.1038/nrclinonc.2012.35] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 7.8] [Reference Citation Analysis]
172 Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of esophageal cancer patients treated with radical intent. Can J Gastroenterol 2008;22:393-8. [PMID: 18414715 DOI: 10.1155/2008/231878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
173 Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. Front Oncol 2020;10:1727. [PMID: 33014854 DOI: 10.3389/fonc.2020.01727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
174 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
175 Chen CZ, Chen JZ, Li DR, Lin ZX, Zhou MZ, Li DS, Chen ZJ. Long-term outcomes and prognostic factors for patients with esophageal cancer following radiotherapy. World J Gastroenterol 2013; 19(10): 1639-1644 [PMID: 23539205 DOI: 10.3748/wjg.v19.i10.1639] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
176 Tomizawa K, Miura Y, Fukui Y, Hanaoka Y, Toda S, Moriyama J, Inoshita N, Ozaki Y, Takano T, Matoba S, Kuroyanagi H. Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report. Int J Surg Case Rep 2017;31:128-31. [PMID: 28135678 DOI: 10.1016/j.ijscr.2017.01.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
177 Oesophago-Gastric Anastomosis Study Group on behalf of the West Midlands Research Collaborative. Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA). BJS Open 2021;5:zrab010. [PMID: 34021328 DOI: 10.1093/bjsopen/zrab010] [Reference Citation Analysis]
178 Reeh M, Nentwich MF, Asani S, Uzunoglu FG, Bockhorn M, Sauter G, Rösch T, Izbicki JR, Bogoevski D. Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? J Gastrointest Surg 2015;19:587-93. [PMID: 25652343 DOI: 10.1007/s11605-015-2762-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
179 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Huang CC, Shih LH, Chen SW, Li SH. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. BMC Cancer 2018;18:837. [PMID: 30126380 DOI: 10.1186/s12885-018-4731-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
180 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
181 Gao HJ, Wei YC, Gong L, Ge N, Han B, Shi GD, Yu ZT. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node-negative esophageal carcinoma. Thorac Cancer 2020;11:2618-29. [PMID: 32755068 DOI: 10.1111/1759-7714.13586] [Reference Citation Analysis]
182 Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study. Cancer Manag Res 2019;11:1299-308. [PMID: 30799956 DOI: 10.2147/CMAR.S195355] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
184 Liu Y, Xie D, Li C, Lin C, Zhao J. Effects of neoadjuvant chemotherapy combined with radiotherapy in patients with advanced esophageal carcinoma. Oncol Lett 2017;14:2803-7. [PMID: 28927038 DOI: 10.3892/ol.2017.6515] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
185 Aoki Y, Toh Y, Taomoto J, Sakaguchi Y, Okamura T. Long-term survival following radical surgery after chemotherapy for esophagogastric adenocarcinoma with extensive lymph node metastases: report of a case. Surg Today 2011;41:1255-9. [PMID: 21874426 DOI: 10.1007/s00595-010-4463-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
186 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N. Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma. Br J Surg 2008;95:840-4. [PMID: 18551472 DOI: 10.1002/bjs.6175] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Khunger A, Buchwald ZS, Lowe M, Khan MK, Delman KA, Tarhini AA. Neoadjuvant therapy of locally/regionally advanced melanoma. Ther Adv Med Oncol 2019;11:1758835919866959. [PMID: 31391869 DOI: 10.1177/1758835919866959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
189 Takao K, Konishi H, Fujiwara H, Shiozaki A, Shoda K, Kosuga T, Kubota T, Arita T, Morimura R, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Okamoto K, Otsuji E. Clinical Significance of Prognostic Nutritional Index in the Treatment of Esophageal Squamous Cell Carcinoma. In Vivo 2020;34:3451-7. [PMID: 33144453 DOI: 10.21873/invivo.12184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
190 Ueki S, Fujishima F, Kumagai T, Ishida H, Okamoto H, Takaya K, Sato C, Taniyma Y, Kamei T, Sasano H. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy. BMC Cancer 2020;20:161. [PMID: 32106831 DOI: 10.1186/s12885-020-6652-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
191 Otsuka R, Akutsu Y, Sakata H, Hanari N, Murakami K, Kano M, Toyozumi T, Takahashi M, Matsumoto Y, Sekino N, Yokoyama M, Okada K, Shiraishi T, Komatsu A, Iida K, Matsubara H. ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. Oncology 2018;94:142-8. [PMID: 29216641 DOI: 10.1159/000484932] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
192 Fareed KR, Soomro IN, Hameed K, Arora A, Lobo DN, Parsons SL, Madhusudan S. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy. World J Gastroenterol 2012; 18(16): 1915-1920 [PMID: 22563171 DOI: 10.3748/wjg.v18.i16.1915] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
193 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
194 Naunheim KS. What's new in general thoracic surgery. J Am Coll Surg 2003;197:88-96. [PMID: 12831929 DOI: 10.1016/S1072-7515(03)00380-6] [Reference Citation Analysis]
195 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
196 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
197 Suttie S, McAteer D, Sheehan M, Nicolson M, Schweiger L, Hammonds S, Smith T, Welch A, Park K. F-18-FDG and C-11-Choline Positron Emission Tomography in Human Esophago-Gastric Cancer: Prediction of Response to Therapy. World J Oncol 2010;1:66-7. [PMID: 29147183 DOI: 10.4021/wjon2010.04.201w] [Reference Citation Analysis]
198 Ao T, Kajiwara Y, Yamada K, Shinto E, Mochizuki S, Okamoto K, Yamadera M, Yonemura K, Ueno H. Cancer-induced spiculation on computed tomography: a significant preoperative prognostic factor for colorectal cancer. Surg Today 2019;49:629-36. [PMID: 30790053 DOI: 10.1007/s00595-019-01780-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Ishihara R, Yamamoto S, Iishi H, Nagai K, Matui F, Kawada N, Ohta T, Kanzaki H, Hanafusa M, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Sugimoto N, Kawaguchi Y, Nishiyama K, Motoori M, Yano M, Hosoki T. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 2012;17:225-32. [PMID: 21735356 DOI: 10.1007/s10147-011-0278-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
200 Kataria K, Verma GR, Malhotra A, Yadav R. Comparison of quality of life in patients undergoing transhiatal esophagectomy with or without chemotherapy. Saudi J Gastroenterol. 2012;18:195-200. [PMID: 22626799 DOI: 10.4103/1319-3767.96454] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
201 Twine CP, Roberts SA, Lewis WG, Dave BV, Rawlinson CE, Chan D, Robinson M, Crosby TD. Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc 2010;24:870-8. [PMID: 19730945 DOI: 10.1007/s00464-009-0681-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
202 Foley KG, Lavery A, Napier E, Campbell D, Eatock MM, Kennedy RD, Bradley KM, Turkington RC. A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma. Sci Rep 2021;11:13061. [PMID: 34158588 DOI: 10.1038/s41598-021-92545-w] [Reference Citation Analysis]
203 Li S, Luk HY, Xia C, Chen Z, Chan PKS, Boon SS. Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. Tumour Virus Res 2021;13:200231. [PMID: 34920177 DOI: 10.1016/j.tvr.2021.200231] [Reference Citation Analysis]
204 Satomi T, Kawano S, Inaba T, Nakagawa M, Mouri H, Yoshioka M, Tanaka S, Toyokawa T, Kobayashi S, Tanaka T, Kanzaki H, Iwamuro M, Kawahara Y, Okada H. Efficacy and safety of endoscopic submucosal dissection for gastric tube cancer: A multicenter retrospective study. World J Gastroenterol 2021; 27(11): 1043-1054 [PMID: 33776371 DOI: 10.3748/wjg.v27.i11.1043] [Reference Citation Analysis]
205 Motoori M, Yano M, Yasuda T, Miyata H, Peng Y, Yamasaki M, Shiraishi O, Tanaka K, Ishikawa O, Shiozaki H, Doki Y. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. Mol Clin Oncol 2013;1:521-6. [PMID: 24649204 DOI: 10.3892/mco.2013.89] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
206 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
207 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
208 Najjar YG, Kirkwood JM. Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Manag 2016;3:149-59. [PMID: 30190883 DOI: 10.2217/mmt-2015-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Chi YK, Chen Y, Li XT, Sun YS. Prognostic significance of the size and number of lymph nodes on pre and post neoadjuvant chemotherapy CT in patients with pN0 esophageal squamous cell carcinoma: a 5-year follow-up study. Oncotarget 2017;8:61662-73. [PMID: 28977894 DOI: 10.18632/oncotarget.18665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
210 Lavery A, Turkington RC. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep (Oxf) 2020;8:411-24. [PMID: 33442473 DOI: 10.1093/gastro/goaa065] [Reference Citation Analysis]
211 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
212 Cools-Lartigue J, Spicer J, Ferri LE. Current status of management of malignant disease: current management of esophageal cancer. J Gastrointest Surg 2015;19:964-72. [PMID: 25650163 DOI: 10.1007/s11605-014-2701-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
213 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Reference Citation Analysis]
214 Zhou F, Zhu M, Wang M, Qiu L, Cheng L, Jia M, Xiang J, Wei Q. Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. J Transl Med. 2016;14:154. [PMID: 27246611 DOI: 10.1186/s12967-016-0903-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
215 Purwar P, Bambarkar S, Jiwnani S, Karimundackal G, Laskar SG, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg 2014;76:494-503. [PMID: 25614726 DOI: 10.1007/s12262-014-1163-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
217 Veeramootoo D, Parameswaran R, Krishnadas R, Froeschle P, Cooper M, Berrisford RG, Wajed SA. Classification and early recognition of gastric conduit failure after minimally invasive esophagectomy. Surg Endosc. 2009;23:2110-2116. [PMID: 19067058 DOI: 10.1007/s00464-008-0233-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
218 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152-1160. [PMID: 23017669 DOI: 10.1016/s1470-2045(12)70348-0] [Cited by in Crossref: 224] [Cited by in F6Publishing: 104] [Article Influence: 22.4] [Reference Citation Analysis]
219 Griffiths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol. 2006;4:82. [PMID: 17118194 DOI: 10.1186/1477-7819-4-82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
220 Maezato K, Nishimaki T, Oshiro M, Yamashiro T, Sasaki H, Sashida Y. Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today 2007;37:1096-101. [PMID: 18030574 DOI: 10.1007/s00595-007-3533-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
221 Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med 2011;15:316-26. [PMID: 20015197 DOI: 10.1111/j.1582-4934.2009.00993.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
222 Ao T, Kajiwara Y, Yonemura K, Shinto E, Mochizuki S, Okamoto K, Kishi Y, Ueno H. Morphological consistency of desmoplastic reactions between the primary colorectal cancer lesion and associated metastatic lesions. Virchows Arch 2020;477:47-55. [PMID: 31932918 DOI: 10.1007/s00428-019-02742-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Law S. Esophagectomy without mortality: what can surgeons do? J Gastrointest Surg 2010;14 Suppl 1:S101-7. [PMID: 19774427 DOI: 10.1007/s11605-009-1028-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
224 Farhan F, Ghalehtaki R, Mahdavi-Seresht S, Meysamie A, Yamrali M, Farazmand B, Mohammadi N, Saraee E, Mir MR, Mir A, Lashkari M, Salarvand S, Esmati E, Samiei F. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. J Gastrointest Cancer 2019;50:907-12. [PMID: 30402826 DOI: 10.1007/s12029-018-0155-7] [Reference Citation Analysis]
225 Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010;17:2184-92. [PMID: 20217248 DOI: 10.1245/s10434-010-0995-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
226 Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245:707-16. [PMID: 17457163 DOI: 10.1097/01.sla.0000254367.15810.38] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
227 Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249-1260. [PMID: 28784312 DOI: 10.1016/s1470-2045(17)30447-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 50] [Article Influence: 20.0] [Reference Citation Analysis]
228 Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713-8. [PMID: 20354452 DOI: 10.1097/JTO.0b013e3181d7776d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
229 Li X, Zhang J, Ye C, Zhu J, Guo K, Guo Y. Impact of chemotherapy and radiotherapy on the survival of elderly esophageal cancer patients undergoing surgery: a SEER database analysis. BMC Gastroenterol 2021;21:430. [PMID: 34794384 DOI: 10.1186/s12876-021-02016-9] [Reference Citation Analysis]
230 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181. [PMID: 21595951 DOI: 10.1186/1471-2407-11-181] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 8.7] [Reference Citation Analysis]
232 Crosby T, Evans M, Gillies RS, Maynard ND. The management of a patient with an operable carcinoma of the oesophagus. Ann R Coll Surg Engl 2009;91:366-70. [PMID: 19622256 DOI: 10.1308/003588409X432428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
233 Smith ZL, Gonzaga JE, Haasler GB, Gore EM, Dua KS. Self-Expanding Metal Stents Improve Swallowing and Maintain Nutrition During Neoadjuvant Therapy for Esophageal Cancer. Dig Dis Sci 2017;62:1647-56. [PMID: 28391413 DOI: 10.1007/s10620-017-4562-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
234 Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067-1074. [PMID: 12934159 DOI: 10.1007/s00268-003-7063-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
235 Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'byrne K, Hollywood D, Muldoon C, Reynolds JV. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9. [PMID: 17024121 DOI: 10.1038/sj.bjc.6603412] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
236 Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett 2014;7:534-40. [PMID: 24396483 DOI: 10.3892/ol.2013.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
237 Noronha V, Joshi A, Jandyal S, Jambhekar N, Prabhash K. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer. Med Oncol 2014;31:188. [PMID: 25148898 DOI: 10.1007/s12032-014-0188-0] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
238 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
239 Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg. 2012;16:1821-1829. [PMID: 22843084 DOI: 10.1007/s11605-012-1979-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
240 Keditsu KK, Jiwnani S, Karimundackal G, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg Oncol. 2013;4:96-104. [PMID: 24426708 DOI: 10.1007/s13193-013-0216-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
241 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. [PMID: 18309943 DOI: 10.1200/JCO.2007.12.9593] [Cited by in Crossref: 860] [Cited by in F6Publishing: 372] [Article Influence: 61.4] [Reference Citation Analysis]
242 Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D, Thompson A. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012;106:955-961. [PMID: 22294182 DOI: 10.1038/bjc.2012.15] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
243 van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8:21. [PMID: 19036143 DOI: 10.1186/1471-2482-8-21] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
244 Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102:1600-1607. [PMID: 20461087 DOI: 10.1038/sj.bjc.6605686] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
245 Kelley ST, Coppola D, Karl RC. Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg. 2004;8:227-231; discussion 231-232. [PMID: 15019913 DOI: 10.1016/j.gassur.2003.11.024S1091255X03003068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Rogers MP, DeSantis AJ, DuCoin CG. Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. Cancers (Basel) 2021;13:4352. [PMID: 34503162 DOI: 10.3390/cancers13174352] [Reference Citation Analysis]
247 Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36:617-622. [PMID: 22223293 DOI: 10.1007/s00268-011-1411-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 9.7] [Reference Citation Analysis]
248 Stein HJ, Feith M, Siewert JR. [Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer]. Chirurg 2009;80:1019-22. [PMID: 19902287 DOI: 10.1007/s00104-009-1734-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
249 Low DE. Update on staging and surgical treatment options for esophageal cancer. J Gastrointest Surg 2011;15:719-29. [PMID: 21487832 DOI: 10.1007/s11605-011-1515-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
250 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
251 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 246] [Article Influence: 49.8] [Reference Citation Analysis]
252 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
253 Yang SM, Hsiao WL, Lin JH, Huang PM, Lee JM. Laparoscopic percutaneous jejunostomy with intracorporeal V-Loc jejunopexy in esophageal cancer. Surg Endosc 2017;31:2678-86. [PMID: 27752817 DOI: 10.1007/s00464-016-5285-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
254 Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. Histopathology 2018;72:1180-8. [PMID: 29465751 DOI: 10.1111/his.13491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
255 Visser E, Franken IA, Brosens LA, Ruurda JP, van Hillegersberg R. Prognostic gene expression profiling in esophageal cancer: a systematic review.Oncotarget. 2017;8:5566-5577. [PMID: 27852047 DOI: 10.18632/oncotarget.13328] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
256 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019;10:1097-102. [PMID: 30854116 DOI: 10.7150/jca.29353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
257 Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg 2011;59:461-6. [PMID: 21751104 DOI: 10.1007/s11748-011-0780-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
258 Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011;11:176. [PMID: 21586140 DOI: 10.1186/1471-2407-11-176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
259 Boonstra JJ, van Marion R, Tilanus HW, Dinjens WN. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus. J Gastrointest Surg 2011;15:48-56. [PMID: 20922573 DOI: 10.1007/s11605-010-1358-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
260 Mantziari S, Teixeira Farinha H, Bouygues V, Vignal JC, Deswysen Y, Demartines N, Schäfer M, Piessen G. Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis. Cancers (Basel) 2021;13:2104. [PMID: 33925512 DOI: 10.3390/cancers13092104] [Reference Citation Analysis]
261 Jamel S, Tukanova K, Markar S. Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review. World J Gastrointest Oncol 2019; 11(9): 741-749 [PMID: 31558978 DOI: 10.4251/wjgo.v11.i9.741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
262 Sato Y, Motoyama S, Wada Y, Wakita A, Kawakita Y, Nagaki Y, Terata K, Imai K, Anbai A, Hashimoto M, Minamiya Y. Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers (Basel) 2021;13:983. [PMID: 33652817 DOI: 10.3390/cancers13050983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
263 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
264 Halliday BP, Skipworth RJ, Wall L, Phillips HA, Couper GW, de Beaux AC, Paterson-Brown S. Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience. Int Semin Surg Oncol 2007;4:24. [PMID: 17937823 DOI: 10.1186/1477-7800-4-24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
265 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
266 Wang Q, Wang F, Lv J, Xin J, Xie L, Zhu W, Tang Y, Li Y, Zhao X, Wang Y, Li X, Guo X. Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis. Oncol Lett 2019;18:1199-206. [PMID: 31423180 DOI: 10.3892/ol.2019.10440] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
267 Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg. 2017;6:131-136. [PMID: 28447001 DOI: 10.21037/acs.2017.03.03] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
268 Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, Imamura Y. Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy. World J Surg 2017;41:2337-44. [PMID: 28432391 DOI: 10.1007/s00268-017-4024-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
269 Miyazono F, Metzger R, Warnecke-Eberz U, Baldus SE, Brabender J, Bollschweiler E, Doerfler W, Mueller RP, Dienes HP, Aikou T, Hoelscher AH, Schneider PM. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91:666-672. [PMID: 15213712 DOI: 10.1038/sj.bjc.6601976] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
270 Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol 2015;8:189-205. [PMID: 26136837 DOI: 10.1177/1756283X15585468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
271 Thomas A, Virdee PS, Eatock M, Lord SR, Falk S, Anthoney DA, Turkington RC, Goff M, Elhussein L, Collins L, Love S, Moschandreas J, Middleton MR. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer 2020;124:131-41. [PMID: 31765988 DOI: 10.1016/j.ejca.2019.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
272 Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JMJ, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. Genome Res 2017;27:902-12. [PMID: 28465312 DOI: 10.1101/gr.214296.116] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
273 Le Bras GF, Farooq MH, Falk GW, Andl CD. Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res 2016;113:236-44. [PMID: 27565381 DOI: 10.1016/j.phrs.2016.08.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
274 Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, Henke M, Hopt UT, Hoeppner J. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg 2013;17:1193-201. [PMID: 23636882 DOI: 10.1007/s11605-013-2212-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
275 Kano K, Aoyama T, Maezawa Y, Hayashi T, Yamada T, Tamagawa H, Sato T, Cho H, Yoshikawa T, Rino Y, Masuda M, Oshima T, Ogata T. Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. In Vivo 2019;33:587-94. [PMID: 30804146 DOI: 10.21873/invivo.11515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
276 Shi Y, Zhang F, Bai Z, Wang J, Qiu L, Li Y, Meng Y, Valji K, Yang X. Orthotopic Esophageal Cancers: Intraesophageal Hyperthermia-enhanced Direct Chemotherapy in Rats. Radiology 2017;282:103-12. [PMID: 27404050 DOI: 10.1148/radiol.2016152281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
277 Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015;CD001556. [PMID: 25988291 DOI: 10.1002/14651858.cd001556.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
278 Gabriel E, Attwood K, Du W, Tuttle R, Alnaji RM, Nurkin S, Malhotra U, Hochwald SN, Kukar M. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. JAMA Surg 2016;151:234-45. [PMID: 26559488 DOI: 10.1001/jamasurg.2015.4068] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
279 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
280 Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer 2018;6:112. [PMID: 30352626 DOI: 10.1186/s40425-018-0428-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
281 Mcglone ER, Khan OA. Prognostic benefit of surgery following chemoradiotherapy for squamous cell carcinoma of the oesophagus. International Journal of Surgery 2012;10:341-4. [DOI: 10.1016/j.ijsu.2012.05.008] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
282 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
283 Findlay JM, Dickson E, Fiorani C, Bradley KM, Mukherjee S, Gillies RS, Maynard ND, Middleton MR. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Eur Radiol 2019;29:6717-27. [PMID: 31278574 DOI: 10.1007/s00330-019-06310-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
284 Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240:791-800. [PMID: 15492560 DOI: 10.1097/01.sla.0000143123.24556.1c] [Cited by in Crossref: 273] [Cited by in F6Publishing: 242] [Article Influence: 15.2] [Reference Citation Analysis]
285 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
286 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol 2016; 22(39): 8750-8759 [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
287 Matsuda S, Kawakubo H, Irino T, Kitagawa Y. Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. Jpn J Clin Oncol 2021:hyab192. [PMID: 34891170 DOI: 10.1093/jjco/hyab192] [Reference Citation Analysis]
288 Bowrey DJ, Evans MD, Clark GW. Impact of methicillin-resistant Staphylococcus aureus infection on outcome after esophagectomy. World J Surg 2007;31:326-31. [PMID: 17171479 DOI: 10.1007/s00268-006-0077-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
289 Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M, Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemp Clin Trials Commun 2021;24:100853. [PMID: 34820548 DOI: 10.1016/j.conctc.2021.100853] [Reference Citation Analysis]
290 Twine CP, Barry JD, Blackshaw GR, Crosby TD, Roberts SA, Lewis WG. Prognostic significance of endoscopic ultrasound-defined pleural, pericardial or peritoneal fluid in oesophageal cancer. Surg Endosc. 2009;23:2229-2236. [PMID: 19118422 DOI: 10.1007/s00464-008-0286-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
291 Tan X, Ma Z, Yan L, Ye W, Liu Z, Liang C. Radiomics nomogram outperforms size criteria in discriminating lymph node metastasis in resectable esophageal squamous cell carcinoma. Eur Radiol. 2019;29:392-400. [PMID: 29922924 DOI: 10.1007/s00330-018-5581-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
292 Garces CA, McAuliffe PF, Hochwald SN, Cance WG. Neoadjuvant therapy in the treatment of solid tumors. Curr Probl Surg 2006;43:457-551. [PMID: 16860653 DOI: 10.1067/j.cpsurg.2006.04.003] [Reference Citation Analysis]
293 Wang F, Gao SG, Xue Q, Tan FW, Gao YS, Wang DL, Mao YS, Zhao J, Li Y, Yu XY, Cheng H, Zhao CG, Yang D, Mu JW. Nomogram for predicting the overall survival of the patients with oesophageal signet ring cell carcinoma. J Thorac Dis 2021;13:1315-26. [PMID: 33841925 DOI: 10.21037/jtd-20-3084] [Reference Citation Analysis]
294 Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis 2017;9:S697-704. [PMID: 28815065 DOI: 10.21037/jtd.2017.03.159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
295 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
296 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
297 Chan DS, Campbell F, Edwards P, Jasani B, Williams GT, Lewis WG. Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surg 2012;2012:804891. [PMID: 22900205 DOI: 10.5402/2012/804891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
298 Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. World J Surg. 2004;28:520-525. [PMID: 15366737 DOI: 10.1007/s00268-004-7417-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 4.4] [Reference Citation Analysis]
299 Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D, Sahu A, Shah S, Ghosh-Laskar S, Patil PS, Mehta SA, Jambhekar N, Mahajan A, Purandare N. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncol Res 2016;23:183-95. [PMID: 27053347 DOI: 10.3727/096504016X14537290676865] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
300 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
301 Miyagaki H, Yamasaki M, Miyata H, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Ishii H, Tanaka F, Mori M, Doki Y. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer 2012;106:947-54. [PMID: 22333595 DOI: 10.1038/bjc.2012.35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
302 Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH. The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. PLoS One 2018;13:e0198800. [PMID: 29889869 DOI: 10.1371/journal.pone.0198800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
303 Kauppila JH, Wahlin K, Lagergren P, Lagergren J. Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer. Sci Rep 2018;8:446. [PMID: 29323261 DOI: 10.1038/s41598-017-18879-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
304 von Rahden BHA, Stein HJ, Siewert JR. Barrett’s esophagus and Barrett’s carcinoma. Curr Oncol Rep 2003;5:203-9. [DOI: 10.1007/s11912-003-0111-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
305 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
306 Gockel I, Sultanov FS, Domeyer M, Goenner U, Junginger T. Developments in esophageal surgery for adenocarcinoma: a comparison of two decades. BMC Cancer 2007;7:114. [PMID: 17603896 DOI: 10.1186/1471-2407-7-114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
307 Gallego J, Cervantes A, Pericay C, Isla D. SEOM clinical guidelines for the treatment of oesophageal cancer. Clin Transl Oncol 2011;13:520-4. [PMID: 21821484 DOI: 10.1007/s12094-011-0691-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
308 Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70-75. [PMID: 14710209 DOI: 10.1038/sj.bjc.6601461] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.2] [Reference Citation Analysis]
309 Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692. [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b] [Cited by in Crossref: 256] [Cited by in F6Publishing: 242] [Article Influence: 15.1] [Reference Citation Analysis]
310 Ohkura Y, Ueno M, Udagawa H. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 2019;17:125. [PMID: 31315622 DOI: 10.1186/s12957-019-1665-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8. [PMID: 19214447 DOI: 10.1007/s11748-008-0337-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
312 Brücher BL, Kitajima M, Siewert JR. Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest 2014;32:497-506. [PMID: 25250506 DOI: 10.3109/07357907.2014.958497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
313 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
314 Mirza A, Brown M, McNulty C, Valentine J, Annesley A, Galloway S, Welch I, West CM, Pritchard S. A pilot study to investigate the role of thymidylate synthase as a marker of prognosis for neoadjuvant chemotherapy in gastric and gastro-oesophageal junction adenocarcinoma. Gastroenterol Res Pract 2013;2013:502153. [PMID: 23533389 DOI: 10.1155/2013/502153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
315 Rahman SA, Walker RC, Lloyd MA, Grace BL, van Boxel GI, Kingma BF, Ruurda JP, van Hillegersberg R, Harris S, Parsons S, Mercer S, Griffiths EA, O'Neill JR, Turkington R, Fitzgerald RC, Underwood TJ; OCCAMS Consortium. Machine learning to predict early recurrence after oesophageal cancer surgery. Br J Surg 2020;107:1042-52. [PMID: 31997313 DOI: 10.1002/bjs.11461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
316 Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget. 2017;8:111795-111806. [PMID: 29340092 DOI: 10.18632/oncotarget.22909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
317 Jenkinson AD, Lim J, Agrawal N, Menzies D. Laparoscopic feeding jejunostomy in esophagogastric cancer. Surg Endosc. 2007;21:299-302. [PMID: 17122985 DOI: 10.1007/s00464-005-0727-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
318 Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013;24:1972-1979. [PMID: 23670093 DOI: 10.1093/annonc/mdt166] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
319 Yano M, Miyata H, Sugimura K, Motoori M, Omori T, Fujiwara Y, Miyoshi N, Yasui M, Ohue M, Akita H, Tomokuni A, Takahashi H, Kobayashi S, Sakon M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy. Mol Clin Oncol 2018;8:434-40. [PMID: 29456850 DOI: 10.3892/mco.2018.1546] [Reference Citation Analysis]
320 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
321 Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H, Haustermans K, Van Veer H, Nafteux P. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019;17:89. [PMID: 31133018 DOI: 10.1186/s12957-019-1630-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
322 Martinez-Isla A. [Oesophago-gastric cancer and minimally invasive surgery]. Cir Esp 2011;89:418-9. [PMID: 21703602 DOI: 10.1016/j.ciresp.2011.05.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
323 Davies L, Mason JD, Roberts SA, Chan D, Reid TD, Robinson M, Gwynne S, Crosby TD, Lewis WG. Prognostic significance of total disease length in esophageal cancer. Surg Endosc 2012;26:2810-6. [PMID: 22534739 DOI: 10.1007/s00464-012-2250-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
324 Fusco N, Bosari S. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol 2016; 22(35): 7926-7937 [PMID: 27672288 DOI: 10.3748/wjg.v22.i35.7926] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
325 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
326 Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 2018;194:125-35. [PMID: 29071366 DOI: 10.1007/s00066-017-1225-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
327 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
328 Sohda M, Saito H, Kuriyama K, Yoshida T, Kumakura Y, Honjyo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Sakai M, Miyazaki T, Fukuchi M, Kuwano H. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. In Vivo 2019;33:501-6. [PMID: 30804133 DOI: 10.21873/invivo.11502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]